$CCL

TSX Tails off Slightly

Canada’s TSX traded near record highs but slipped 68.19 points to 36,593.95 as investors weighed earnings and softer U.S. PPI. The Canadian dollar fell to 71.72 U.S. cents. CCL Industries rose 3.7% after beating sales; Pan American Silver fell 10% after missing profit. Brookfield’s distributable EPS rose, shares little changed.

Original reporting
Published Aug 13, 2026, 7:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 7:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TSX Tails off Slightly — source image
Decision brief

The 30-second read

$CCLBullishLow
01

Why it matters

The only clearly investable catalysts in the text are earnings beats/misses for a few Canadian-listed companies, especially Pan American Silver’s 10% drop on a profit miss. Other listed price changes appear to be tape-level moves without disclosed drivers.

02

Market read

Traders get a quick read on which Canadian earnings prints surprised (CCL up, Pan American Silver down) and how commodities and U.S. inflation data are shaping risk sentiment.

03

What to watch

For the earnings movers (CCL, Brookfield, Pan American Silver, Stantec), the text omits guidance, margin, and balance-sheet details that typically determine whether the initial reaction persists.

Relevance 5/10Novelty 3/10Timing: Thursday afternoon TSX tape, with same-day earnings reactions cited.

Background

A TSX market wrap describes index performance near record highs alongside selected Canadian earnings outcomes and commodity moves.

Company-level read

Ticker impact

$CCLBullishMedium confidence
Context

CCL Industries topped second-quarter sales estimates, with shares up $3.36, or 3.7%, to $94.94.

Expected impact

Likely supports continued relative strength into the next session, with follow-through dependent on guidance details not provided here.

Evidence & confidence

The article cites a specific earnings beat and same-day price reaction, but provides no guidance or margin detail to gauge durability.

$BHCNeutralLow confidence
Context

Bausch Health rose 13 cents, or 1.5%, to $8.75 in the TSX tape.

Expected impact

Limited incremental edge; any follow-through would likely be driven by broader market/sector flows.

Evidence & confidence

No earnings or company-specific news is described for Bausch Health beyond the price change.

$BAMNeutralLow confidence
Context

Brookfield posted a rise in second-quarter distributable earnings per share, though shares were little changed.

Expected impact

Near-term impact likely muted; traders may fade unless additional guidance details emerge elsewhere.

Evidence & confidence

The article confirms an earnings improvement but provides no magnitude versus expectations or guidance, and notes shares were little changed.

$PAMBearishMedium confidence
Context

Pan American Silver missed quarterly adjusted profit estimates, with the stock down $7.27, or 10%, to $65.83.

Expected impact

Elevated risk of further weakness or volatility until investors digest the miss drivers and outlook.

Evidence & confidence

The text provides both the miss and a large immediate price reaction, which typically reflects a meaningful expectation reset.

Market effects

Gold and materials were the biggest drags (gold down 2.6%, materials down 2.2%), implying pressure on precious-metals and cyclical exposures.

Canada FX weakened slightly (CAD down to 71.72 cents U.S.), which can affect TSX earnings translation and risk appetite.

U.S. PPI came in softer than expected and oil/gold moved lower, supporting a risk-on tone for North American equities while pressuring commodities-linked names.

Counterpoint

The article is a market wrap; some single-name moves (e.g., Bausch, Extendicare, Sienna) may be noise from index/sector flows rather than investable catalysts.

Key entities

  • Pan American Silver

    Missed quarterly adjusted profit estimates and fell 10% to $65.83.

  • CCL Industries

    Topped second-quarter sales estimates and rose 3.7% to $94.94.

  • Brookfield

    Reported higher second-quarter distributable earnings per share, but shares were little changed.

  • Stantec

    Beat second-quarter adjusted profit estimates driven by acquisition growth.

  • Bausch Health

    Stock rose modestly to $8.75 during the session.

Related articles

$BAMMed

Brookfield Wealth Solutions assets pass $200bn

Brookfield Wealth Solutions said total assets rose to $205.7 billion at June 30 from $157.2 billion at end-2025 after completing its acquisition of UK insurer Just Group. Distributable operating earnings increased 23% to $488 million in Q2. Net income fell to $149 million due to mark-to-market losses. The firm reported $35 billion cash and $43 billion longer-term liquid investments.

$BHCMedAI 8/10

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Bausch Health Companies (BHC) shares rose nearly 40% in July after a Canada regulatory update and a beat-and-raise quarter. Prokedi was added to Quebec’s formulary. In Q2, revenue and adjusted results improved, with adjusted EPS $1.26 vs $1.23 expected, and net income $476M. Bausch raised 2026 revenue to $10.79B-$11.04B and adjusted EBITDA to $4.05B-$4.18B.

$BHCMedAI 9/10

Bausch Health (BHC) Q2 2026 Earnings Call Transcript

Bausch Health (NYSE:BHC) reported Q2 2026 results excluding Bausch + Lomb: revenue $1.458B (+16%), adjusted EBITDA $865M (+28%), margin 59.3% (+530 bps), and adjusted operating cash flow $471M. Net debt fell to $13.7B. Full-year 2026 guidance was raised. Headwinds include Aplenzin LOE and CMS rebate impacts.

$BAMMedAI 8/10

Brookfield Raises Record $77 Billion Driven by Insurance Arm

Brookfield Asset Management raised a record $77 billion in Q2, led by its credit unit, and said distributable earnings rose 15% to $707 million, or 44 cents per share. Credit raised $51 billion, including a $40 billion mandate tied to Just Group annuities. Brookfield invested $21 billion and generated $11 billion from asset sales, and expects more flagship fundraising next year.